The PulmoSphere™ platform for pulmonary drug delivery

Therapeutic Delivery

Volumn 5, Issue 3, 2014, Pages 277-295

  Weers, Jeffry ^a   Tarara, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BUDESONIDE; CIPROFLOXACIN; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LEUPRORELIN; SALBUTAMOL; TOBRAMYCIN;

DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRY POWDER INHALER; HUMAN; LIQUID VENTILATION; METERED DOSE INHALER; NEBULIZER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SUSPENSION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; MODELS, CHEMICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; POROSITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84896795789     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.3     Document Type: Review

References (88)

1. Clinical trials. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE)(RESPIRE 1). www.clinicaltrials.gov/ct2/show/ NCT01764841
2. Clinical trials. Efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to severe COPD (PINNACLE 1). www.clinicaltrials.gov/ct2/ show/NCT01854645
3. Tarara TE, Weers JG, Dellamary LA. Engineered powders for inhalation. Proc. Resp. Drug Deliv. 413-416 (2000).
4. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25, 999-1022 (2007).
5. Ivey J W, Vehring R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Computers Chem. Eng. 34, 1036-1040 (2010).
6. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv. 4, 297-313 (2007).
7. Weers JG, Tarara T, Malcolmson R, Leung D. Embedded crystals in low density particles: formulation, manufacture, and properties. Proc. Resp. Drug Del. 297-304 (2006).
8. Weers JG. Dispersible powders for inhalation applications. Innov. Pharm. Tech. 1(7), 111-116 (2000).
9. Weers J, Clark A, Challoner P. High dose inhaled powder delivery: challenges and techniques. Proc. Resp. Drug Del. 281-288 (2004).
10. ® powder. Pharm. Res. 19, 689-695 (2002).
11. Newhouse MT, Hirst PH, Duddu SP et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124, 360-366 (2003).
12. Weers JG, Bell J, Chan HK et al. Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv. 23, S5-S23 (2010).
13. Weers JG, Ung K, Le J et al. Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject's inhalation maneuver. J. Aerosol Med. Pulm. Drug Deliv. 26, 56-68 (2013).
14. Weers JG, Ung K, Chan L et al. Minimizing human factors effects through improved inhaler design. Proc. Resp. Drug Deliv. 217-226 (2012).
15. Bot AI, Tarara TE, Smith DJ et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 17, 274-282 (2000).
16. Bot AI, Smith DJ, Bot S et al. Receptor-mediated targeting of spray-dried lipid particles co-formulated with immunoglobulin and loaded with a prototype vaccine. Pharm. Res. 18, 971-979 (2001).
17. Dellamary L, Smith DJ, Bloom A et al. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 95, 489-500 (2004).
18. Smith DJ, Bot S, Dellamary L et al. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 21, 2805-2812 (2003).
19. Wang L, Bot S, Smith D et al. Basic immunological properties of spray-dried lipid microparticles developed for nasal and systemic administration of vaccines. STP Pharma Sci. 12, 53-61 (2002).
20. Dellamary LA, Tarara TE, Smith DJ et al. Hollow porous particles in metered dose inhalers. Pharm. Res. 17, 168-174 (2000).
21. Weers JG, Tarara TE, Gill H et al. Homodispersion technology for HFA suspensions: particle engineering to reduce dosing variance. Proc. Resp. Drug Del. 91-97 (2000).
22. Hirst PH, Elton RC, Pitcairn GR et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm. Res. 19, 258-264 (2002).
23. Tarara TE, Hartman M, Gill H et al. Characterization of suspension-based metered dose inhaler formulations comprised of spray-dried budesonide crystals dispersed in HFA-134a. Pharm. Res. 21, 1607-1161 (2004).
24. Smith DJ, Gambone LM, Tarara T et al. Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits. Pharm. Res. 18, 1556-1561 (2001).
25. Dickson EW, Heard SO, Tarara TE et al. Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia. Crit. Care Med. 30, 393-395 (2002).
26. Dickson EW, Doern GV, Trevino L et al. Prevention of descending pneumonia in rats with perflubron-delivered tobramycin. Acad. Emerg. Med. 10, 1019-1023 (2003).
27. Lechuga-Ballesteros D, Noga B, Vehring R et al. Novel cosuspension metered-dose inhalers for combination therapy of chronic obstructive pulmonary disease and asthma. Future Med. Chem. 3, 1703-1718 (2011).
28. Vehring R, Lechuga-Ballesteros D, Joshi V et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 28, 15015-15023 (2012).
29. Lechuga-Ballesteros D, Vehring R, Dwivedi SK. Poster: a novel cosuspension MDI platform: scientific foundations of mono, dual and triple combination products. Proc. RDD Europe 101-111 (2011).
30. Cummings RH, Joshi V, Lechuga-Ballesteros D et al. Poster: performance advantages of Pearl co-suspension formulations for manufacturing of metered dose inhalers. Proc. RDD Europe 387-390 (2011).
31. Noga B, Cummings RH, Joshi V et al. Product performance, stability, and dose proportionality of glycopyrrolate metered dose inhaler with sub-microgram doses using co-suspension technology. Respir. Drug Deliv. 2, 645-648 (2012).
32. Lechuga-Ballesteros D, Schroeder J, Alluri S et al. Dose proportionality in a triple therapy co-suspension pMDI with multiple strengths of an inhaled corticosteroid. RDD Europe 2, 339-342 (2013).
33. Kirkpatrick WR, Najvar LK, Vallor AC et al. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 67, 970-976 (2012).
34. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 24, 175-182 (2011).
35. Haynes A, Nakamura J, Heng C et al. Aerosol performance of tobramycin inhalation powder. Proc. Resp. Drug Deliv. 701-706 (2010) (2010).
36. Maltz D, Paboojian SJ. Device engineering insights into TOBI Podhaler: a development case study of high efficiency powder delivery to cystic fibrosis patients. RDD Europe 55-66 (2011).
37. Haynes A, Ament B, Heng C et al. In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI Podhaler) using inspiratory flow rates from cystic fibrosis patients (abstract). Presented at: The North American Cystic Fibrosis Conference, Salt Lake City, UT, USA, 17-19 September 2013.
38. Geller DE, Konstan MW, Smith J et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 42, 307-313 (2007).
39. Konstan M, Flume PA, Kappler M et al. Safety, efficacy, and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibrosis 10, 54-61 (2011).
40. Konstan M, Geller DE, Minic P et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmonol. 46, 230-238 (2011).
41. Galeva I, Konstan MW, Higgins M et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr. Med. Res. Opin. 29(8), 947-956 (2013).
42. Geller DE, Nasr SJ, Piggott S et al. Tobramycin inhalation powder in cystic fibrosis: response by age group. Respir. Care doi:10.4187/respcare.02264 (2013) (Epub ahead of print).
43. Vandevanter DR, Geller DE. Tobramycin administered by the TOBI Podhaler for persons with cystic fibrosis: a review. Med. Devices (Auckland) 4, 179-188 (2011).
44. Parkins MD, Elborn JS: Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev. Respir. Med. 5, 609-622 (2011).
45. Gupta A, Tarara T, Miller D et al. A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections. AAPS J. 13(S2), R6156 (2011).
46. Stass H, Nagelschmitz J, Willmann S et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I st udy. Clin. Drug Investig. 33(6), 419-427. (2013).
47. Stass H, Weimann B, Nagelschmitz J et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a Phase I, randomized, dose-escalation study. Clin. Ther. 35 (10), 1571-1581 (2013).
48. Antoniu S, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opin. Invest. Drugs 22(5), 671-673 (2013).
49. Wilson R, Welte T, Polverino E et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a Phase II randomised study. Eur. Resp. J. 41, 1107-1115 (2013).
50. Tokimatsu I, Hiramatsu K, Morimoto T et al. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir.Crit. Care Med. 183, A3105 (2011).
51. Marjason J, Orevillo CJ, St Rose E et al. Assessment of safety and pharmacokinetic profile of a novel fixed dose combination of glycopyrrolate and formoterol HFA MDI in healthy volunteers. Am. J. Respir. Crit. Care Med. 181, A4455 (2010).
52. Reisner C, Fogarty C, Spangenthal S et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared with its components alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase IIb study in patients with COPD. Am. J. Respir. Crit. Care Med. 183, A6435 (2011).
53. Weers JG, Schutt EG, Dellamary LA et al.: US6309623 (2001).
54. Dellamary LA, Tarara TE, Kabalnov A et al.: US6433040 (2002).
55. Tarara TE, Weers JG, Kabalnov AS et al.: US6565885 (2003).
56. Schutt EG, Tarara TE, Dellamary LA et al.: US6946117 (2005).
57. Dellamary LA, Riess J, Schutt EG et al.: US7871598 (2011).
58. Weers JG, Tarara TE, Dellamary LA et al.: US7442388 (2008).
59. Bot A, Tarara TE, Weers JG et al.: US6630169 (2003).
60. Weers JG, Huang D, Miller DP et al.: US provisional application (US61/784865) (2013).
61. Weers JG, Tarara TE: US 20110123626 (2011).
62. Hartman M, Tarara TE, Teung P, Weers JG: US provisional application (US61/784842) (2013).
63. Weers JG, Rao N, Huang D et al.: WO2012/106575A1 (2012).
64. Krafft MP, Riess JG, Weers JG. The Design and Engineering of Oxygen-Delivering Fluorocarbon Emulsions. In: Submicron Emulsions in Drug Targeting and Delivery. Benita S (Ed.). Harwood Academic Publishers, Amsterdam, The Netherlands, 235-333 (1998).
65. Tsapis N, Bennett D, Jackson B et al. Troja n particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA 99, 12001-12005 (2002).
66. Joris L, Quinton PM. Filter paper equilibration as a novel technique for in vitro studies of the composition of airway surface fluid. Am. J. Physiol. 263, L243-L248 (1992).
67. Leach CL, Greenspan JS, Rubenstein SD et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N. Eng. J. Med. 335, 761-767 (1996).
68. Gauger PG, Pranikoff T, Schreiner RJ et al. Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. JAMA 275(5), 383-389 (1996).
69. Hirschl RB, Conrad S, Kaiser R et al. Partial liquid ventilation in patients with ARDS: a multicenter Phase I-II trial. Adult PLV study group. Crit. Care Med. 24(1), 16-22 (1996).
70. Chan HK, Kwok PCL. Novel Particle Production Technologies for Inhalation Products (Chapter 4). In: Inhalation Drug Delivery: Techniques and Products. Colombo P, Traini D, Buttini F (Eds). John Wiley & Sons, Ltd, Chichester, UK (2013).
71. Snyder HE, Vosberg MJ, Varga CM: US8524279 (2013).
72. Begat P, Morton DAV, Staniforth JN. The cohesive-adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm. Res. 21, 1591-1597 (2004).
73. Zeng XM, Martin GP, Marriott C, Pritchard J. The inf luence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm. 200, 93-106 (2000).
74. Faithfull NS, Weers JG: US5655521 (1997).
75. Fuhrman BP: US5437272 (1995).
76. Clinical trials. Phase 1 study evaluating the safety and pharmacokinetics of budesonide, glycopyrronium, and formoterol fumarate inhalation aerosol (BGF MDI) in healthy volunteers. www.clinicaltrials.gov/ct2/show/NCT01980615
77. Dunbar C. Porous particles for inhalation: the science behind their improved dispersibility. Proc. Resp. Drug Deliv. 10, 307-313 (2006).
78. Dixon J, Simpson I. Appealing to users-designing inhalers to maximize compliance and minimize misuse. RDD Europe 117-127 (2009).
79. Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J. Aerosol Med. Pulm. Drug Deliv. 19, 473-483 (2006).
80. Thorsson L, Edsbäcker S, Källén A, Lfdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. J. Clin. Pharmacol. 52, 529-538 (2001).
81. Pavkov R, Geller DE, Ament B et al. Dynamic inspiratory flow characteristics through the T-326 dry powder inhaler in cystic fibrosis patients. RDD Europe 325-328 (2013).
82. Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. RDD Europe 105-116 (2009).
83. Laube BL, Janssens HM, De Jongh FHC et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Resp. J. 37(6), 1308-1331 (2011).
84. Borgström L, Bondesson E, Moren F et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7, 69-73 (1994).
85. Taki M, Zeng XM, Mariott C, Martin G. An assessment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Andersen cascade impactor (ACI). Proc. Respir. Drug Deliv. 655-657 (2006).
86. Anderson GJM, Bonney SG, Davies MB et al.: WO2003061743 (2003).
87. Newton DW. Maillard reactions in pharmaceutical formulations and human health. Int. J. Pharm. Compd. 15(1), 32-40 (2011).
88. Lipinski CA, Lombardo F, Dominy BW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).